

## M.PHARM. IN REGULATORY AFFAIRS

## **COURSE STRUCTURE & SYLLABI**

## SEMESTER - I

S.	Course	Course Name	Hour	s per w	per week		
No.	codes		L	T	P		
1.	21S11101	Good Regulatory Practices	4	-	-	4	
2.	21S11102	Drug Regulatory Affairs	4	-	-	4	
3.	21S11103	Total quality Management	4	-	-	4	
4.	21S11104	Documentation and Regulatory Writing	4	-	-	4	
5.	21S11105	Regulatory Practices & Documentation Lab	-	-	6	3	
6.	21S11106	Drug Regulatory Affairs Lab	-	-	6	3	
7.	21DAC101a 21DAC101b 21DAC101c	Audit Course – I English for Research paper writing Disaster Management Sanskrit for Technical Knowledge	2	-	-	0	
8.	21S11107	Seminar/Assignment	-	1	6	4	
		Total	18	1	18	26	

## SEMESTER - II

S.No.	Course	Course Name	Hou	ırs per	week	Credits
	codes		L	T	P	
1.	21S11201	Regulatory Aspects of Drugs & Cosmetics	4	-	-	4
2.	21S11202	Regulatory Aspects of Herbal & Biologicals	4	-	-	4
3.	21S11203	Regulatory Aspects of Medical Devices	4	-	-	4
4.	21S11204	Regulatory Aspects of Food & Nutraceuticals	4	-	-	4
5.	21S11205	Regulatory Aspects of Drugs & Cosmetics Lab	-	-	6	3
6.	21S11206	Regulatory Aspects of Medical Devices Lab	-	-	6	3
7.	21DAC201a 21DAC201b 21DAC201c	Audit Course – II Pedagogy Studies Stress Management for Yoga Personality Development through Life Enlightenment Skills	2	1	1	0
8.	21S11207	Seminar/Assignment	-	1	6	4
		Total	18	1	18	26



## M.PHARM. IN REGULATORY AFFAIRS

## COURSE STRUCTURE & SYLLABI

## **SEMSTER - III**

S.No.	Course	Course Name	Hours per week		eek	Credits
	codes		L	T	P	
1.	21DRM101	Research Methodology and Intellectual Property Right	4	-	-	4
	21SOE301d 21SOE301f	Open Electives Biological Screening methods Stability of Drugs and Dosage forms Pharmacoepidemiology and Pharmacoeconomics	3	1	1	3
3.	21S11301	Teaching Practice/Assignment	-	-	4	2
4.	21S11302	Comprehensive viva voce	-	-	4	2
5.	21S11303	Research Work - I	ı		24	12
		Total	7	-	32	23

## **SEMESTER - IV**

S.No.	Course	Course Name	Hours per week		Hours per week		veek	Credits
	codes		L	T	P			
1.	21S11401	Journal Club	2	-	-	2		
2.	21S11302	Research Work-II	3	-	30	18		
		Total	5	-	30	20		



## M.PHARM. IN REGULATORY AFFAIRS

## **COURSE STRUCTURE & SYLLABI**

<b>Course Code</b>	GOOD REGULATORY PRACTICES	L	T	P	C
<b>21S11101</b>	GOOD REGULATORY PRACTICES	4	0	0	4
	Semester			I	
Course Objecti	ves:				
This course is de	esigned to impart fundamental knowledge on various Good Regulator	ory F	racti	ices v	/iz.,
cGMP, GLP, C	SALP and GDP for Pharmaceuticals, Cosmetics, Food & Nutrace	eutic	als,	Med	ical
devices, In-vitro	Diagnostic Medical Devices (IVDs) and biological products and	d ur	nders	tand	the
rationale behind	these requirements and will propose ways and means of complying	with	ther	n	
<b>Course Outcom</b>	nes (CO): Student will be able to				
At completion o	f this course it is expected that students will be able to understand				
The key regulate	ory and compliance elements with respect to Good Manufacturing P	ract	ices,	D G	ood
Laboratory Prac	etices, Good Automated Laboratory Practices and Good Documen	ntati	on P	racti	ces.
Prepare and imp	element the check lists and SOPs for various Good Regulatory Practice	ctice	s. In	ıplen	ient
Good Regulator	y Practices in the Healthcare and related Industries. Prepare for t	he r	eadii	ness	and
conduct of audit	s and inspections.				
UNIT - I					
Principles of Gl	Manufacturing Practices: Introduction, US C GMPp Part 210 a MP (Directive 91/356/EEC) Article 6 to Article 14 and WHO C	GM	IP gu	uideli	
	cal device and IVDs Global Harmonization Task Force (GHTF) Gui	uanc	e do	cs.	
UNIT - II	my Durational Introduction LICEDA CLD Decoulations (Cubmout A		Cych		<u>V)</u>
	ry Practices: Introduction, USFDA GLP Regulations (Subpart A				
	GLP inspection process, Documentation, Audit, goals of Laborator are of GLP regulations, relevant ISO and Quality Council of India (Quality Council of India)				
UNIT - III	are of GLF regulations, relevant 150 and Quanty Council of India (C	<u>(C1)</u>	Stai	luaru	8
	ed Laboratory Practices: Introduction to GALP, Principles of		A I D	<u> </u>	I D
Requirements, 2 21CFR Part 11,	SOPs of GALP, Training Documentation,21 CFR Part 11, Gene Software Evaluation checklist, relevant ISO and QCI Standards.				
UNIT - IV					
	ion Practices: Introduction to GDP, Legal GDP requirements				
•	onnel, Documentation, Premises and Equipment, Deliveries to Cus				
	, Provision of information, Stability testing principles, WHO	<b>JDP</b>	, US	SP C	iDP
(Supply chain in	tegrity), relevant CDSCO guidance and ISO standards				
UNIT - V					
Quality manage	ment systems: Concept of Quality, Total Quality Management, Q	ualit	y by	desi	ign,
Six Sigma conc	ept, Out of Specifications (OOS), Change control. Validation: Typ	es c	of Va	lidat	ion,
Types of Qualif	ication, Validation master plan (VMP), Analytical Method Validati	on. `	Valic	lation	ı of
utilities, [Compr	ressed air, steam, water systems, Heat Ventilation and Air conditioni	ng (	HVA	(C)	and
Cleaning Valida	tion. The International Conference on Harmonization (ICH) process	s, IC	H gu	ıideli	nes
to establish qual	lity, safety and efficacy of drug substances and products, ISO 1348	35, \$	Sch N	ΛIII	and
_	DSCO regulatory guidance documents.				
Textbooks:				_	

3. Establishing a cGMP Laboratory Audit System, A practical Guide by David M. Bleisner,

1.Good Laboratory Practice Regulations, by Sandy Weinberg, Fourth Edition Drugs and the

2.Good Pharmaceutical Manufacturing practice, Rational and compliance by John Sharp, CRC

Pharmaceutical Sciences, Vol.168

Press



## JAWAHARLAL NEHRU TECHNOLOGICAL UNIVERSITY ANANTAPUR (Established by Govt. of A.P., ACT No.30 of 2008) ANANTHAPURAMU – 515 002 (A.P) INDIA

## M.PHARM. IN REGULATORY AFFAIRS

## COURSE STRUCTURE & SYLLABI

Wiley Publication.

- 4. How to practice GLP by PP Sharma, Vandana Publications.
- 5. Laboratory Auditing for Quality and Regulatory compliance bu Donald C. Singer, Drugs and the Pharmaceutical Sciences, Vol.150
- 6. Drugs & Cosmetics Act, Rules & Amendments



## M.PHARM. IN REGULATORY AFFAIRS

### **COURSE STRUCTURE & SYLLABI**

Course Code	DDIIC DECHI ATODY AFEAIDS	L	T	P	C
21S11102	DRUG REGULATORY AFFAIRS  Semester	4	0	0	4
	Semester			I	
Course Objectives:					

### Course Objectives:

The topics which are present in the Drug regulatory affairs are very much useful which increases the knowledge regarding the regulatory aspects in the pharmaceutical industries.

## Course Outcomes (CO): Student will be able to

Students will come to know the different competent regulatory authorities globally. Students be aware of technical aspects pertaining to the marketing authoritization application (MAA) The regulatory guidelines and directions framed by the regulatory authorities will be helpful to place the drug products in market for marketing approvals.

### UNIT - I

## **Drug Regulatory Aspects (India)**

- 1. Indian drug regulatory authorities, Central and State regulatory bodies (FDA)
- 2. Drugs and Cosmetics Act and Rules with latest Amendments (Selective)
- 3. Special emphasis Schedule M and Y
- 4. New drugs Importation, Registration, development, Clinical Trials, BE NOC & BE studies
- 5. Various Licenses Test Lic., Import lic., for testing of drugs and API's, Manufacturing Contract and Loan licence manufacturing.

### **UNIT - II**

## **Manufacturing Practices (GMP)**

- 1. Indian GMP certification, WHO GMP certification.
- 2. ICH guidelines for stability testing and other relevant ones (Q1-Q10)
- 3. Export permissions and manufacturing for semi-regulated countries
- 4. Understanding of the plant layouts with special emphasis on the environment & safety. (HVAC, Water Systems, Stores Management, Effluent etc.)
- 5. Quality Assurance and Quality Control Basic understanding for in-built quality.

## **UNIT - III**

A detailed study of regulatory aspects that affect drug product design, manufacture and distribution in a developed country such as USA and in a developing country such as Brazil, Hatch Waxman Act; Bolar Provisions and other FDA Regulations. Regulatory aspects of pharmaceutical and bulk drug manufacture, regulatory drug analysis.

## UNIT - IV

Documentation related to manufacturing, cleaning methods, retention samples and records, quality control, batch release documents, distribution records, complaints and recalls. Quality, safety and legislation for cosmetic products and herbal products.

### IINIT - V

## Governing Regulatory Bodies across the globe. Country Authority Submission

- a. U.S Food & Drug Administration USDMF
- b. Canada Therapeutic Product Directorate DMF
- c. Europe
  - 1) European Medicines Agency (EMEA/ National Authorities) EDMF
  - 2) European Directorate for Quality of Medicines CEP/COS & Health Care Products.
  - 3) MHRA Medicines and Health Care Products Regulatory Agency
- d. Product Filing
- e. Responding Regulatory Deficiencies
- f. Final Approval Procedure



## JAWAHARLAL NEHRU TECHNOLOGICAL UNIVERSITY ANANTAPUR (Established by Govt. of A.P., ACT No.30 of 2008) ANANTHAPURAMU – 515 002 (A.P) INDIA

## M.PHARM. IN REGULATORY AFFAIRS

## COURSE STRUCTURE & SYLLABI

Preparation, review and submission of Drug Master Files to Regulatory Authorities as per their specific requirements.

## **Textbooks:**

- 1. Original laws published by Govt. of India.
- 2. Text Book of Forensic Pharmacy by Mithal B. M.; Vallabh Prakashan, New Delhi.
- 3. Laws of Drugs in India by Hussain.
- 4. Text Book of Forensic Pharmacy by Jain N. K.; Vallabh Prakashan, New Delhi.
- 5. Pharmaceutical Regulatory Affairs - Selected Topics, CVS Subramanian and J Thimmasetty, Vallabh Prakashan Delhi – 2013



## M.PHARM. IN REGULATORY AFFAIRS

## **COURSE STRUCTURE & SYLLABI**

Course Code	TOTAL OHALITY MANACEMENT	L	T	P	C
21S11103	TOTAL QUALITY MANAGEMENT	4	0	0	4
	Semester	I			
Course Objecti	ves:				
	nagement constitutes very useful chapter like –good manufacturing Which increases the knowledge of students in various quality control				
Course Outcon	nes (CO): Student will be able to				
GCP, GLP, US students to acq	anagement helps the students to learn the established regulatory guing FDA, WHO, ISO etc to become a perfect budding pharmacist. It uses the vast knowledge regarding the quality control aspects of differ requirements throughout the world.	is v	ery ı	ısefu	1 to
UNIT - I					
Concepts and Pl	nilosophy of TQM, GLP, GMP (orange guide).				
UNIT - II					
Drug regulatory	and accrediting agencies of the world (USFDA, TGA, ICH, WHO,	ISO	etc.)		
UNIT - III					
Good manufactu	iring practices: Organization and personnel, responsibilities, training	, hy	giene	e	

Premises: Location, design, plant layout, construction, maintenance and sanitation, environmental

Premises: Location, design, plant layout, construction, maintenance and sanitation, environmental control, utilities and services like gas, water, maintenance of sterile areas, control of contamination. Equipments: Selection, purchase specifications, maintenance, clean-in-place, sterilize-in-place, methods (TP and STP).

Raw materials: Purchase specifications, maintenance of stores, selection of vendors, controls on raw materials and finished dosage forms. Manufacture of and controls on dosage forms: Manufacturing documents, master formula, batch formula records, standard operating procedures, quality audits of manufacturing processes and facilities.

In process quality controls on various dosage forms: Sterile and non-sterile, standard operating procedures for various operations like cleaning, filling, drying, compression, coating, disinfections, sterilization, membrane filtration etc.,

Packaging and labeling control, line clearance, reconciliation of labels, cartons and other packaging materials.

Quality Control Laboratory: Responsibilities, good laboratory practices, routine controls instruments, reagents, sampling plans, standard test procedures, protocols, non-clinical testing, controls on animal house. Data generation and storage, quality control documents, retention samples, records and audits of quality control facilities. Finished products release, quality review, quality audits, batch release document.

## UNIT - IV

Regulatory Considerations for Pre-clinical and Clinical Evaluation: Pre-clinical requirements currently in use. Regulatory requirements of single dose and repeat dose toxicity studies. Study of specific toxicities such as mutagenicity, carcinogenicity and teratoginicity. Animal pharmacokinetics and toxicokinetics. Regulatory requirements of clinical evaluation, pharmacokinetics in man genetic polymorphism. Design and interpretation of clinical trials. Quality assurance standards as per ISO.

## UNIT - V

Globalization of drug industry, present status and scope of pharmaceutical industry in India. WHO and NABL certification, ICH guidelines for manufacturing and quality assurance of drug



## JAWAHARLAL NEHRU TECHNOLOGICAL UNIVERSITY ANANTAPUR (Established by Govt. of A.P., ACT No.30 of 2008) ANANTHAPURAMU – 515 002 (A.P) INDIA

## M.PHARM. IN REGULATORY AFFAIRS

## **COURSE STRUCTURE & SYLLABI**

formulation.

## **Textbooks:**

- 1. Guidelines for Developing National Drug Policies; WHO Publications, 1998.
- 2. Quality Assurance of Pharmaceuticals—A Compendium of Guidelines and Related Materials, Vol.—1; WHO Publications.
- 3. A Guide to Total Quality Management by Kaushik Maitra and Sedhan K. Ghosh.
- 4. GMP by Mehra.
- 5. How to Practice GMP by P.P. Sharma.
- 6. ISO 9000 and Total Quality Management by Sadhan K. Ghosh.
- 7. Good Manufacturing Practices for Pharmaceuticals-A Plan for Total Quality Control by Sidney
- H. Willing & James R Stoker. (Drugs & Pharm. Sciences) Vol. 78; Marcel Dekker Inc.
- 8. OPPI-Quality Assurance, USP.
- 9. Current good manufacturing practices for pharmaceuticals by Manohar A. Potdar
- 10. Quality assurance and quality management in pharmaceutical industry by Y. Anjaneyulu and marayya
- 11. Total Quality Management, An integrated Approach by D. R. Kiran, BS Publications
- 12. Total Quality Management, 3rd edition by Joel E. Ross. CRC press



## M.PHARM. IN REGULATORY AFFAIRS

## **COURSE STRUCTURE & SYLLABI**

Course Code	DOCUMENTATION AND REGULATORY	L	T	P	C
21S11104	WRITING	4	0	0	4
	Semester			I	
Course Objectives:					
	ned to impart fundamental knowledge on documentation				
	es involved in regulatory writing and submission to agencies.				
`	CO): Student will be able to				
<ul> <li>Know the va</li> </ul>	rious documents pertaining to drugs in pharmaceutical industry				
<ul> <li>Understand t</li> </ul>	the basics of regulatory compilation				
<ul> <li>Create and a</li> </ul>	ssemble the regulation submission as per the requirements of ag	enci	ies		
<ul> <li>Follow up th</li> </ul>	e submissions and post approval document requirements				
UNIT - I					
Documentation in p	pharmaceutical industry: Exploratory Product Development B	rief	(EP	DB)	for
-	Drug product, Product Development Plan (PDP), Product Dev				
•	rmula Record, Batch Manufacturing Record and its cal	•		-	
	h Packaging Records, Print pack specifications, Distribution re-				
of Analysis (CoA), S	Site Master File and Drug Master Files (DMF).				
UNIT - II	<u> </u>				
Dossier preparation	and submission: Introduction and overview of dossier	s, c	conte	nts	and
organization of doss	ier, binders and sections, compilation and review of dossier. Pa	per	subr	nissi	ons,
overview and modu	ales of CTD, electronic CTD submissions; Electronic subm	issi	on:	Planr	ning
electronic submissio	n, requirements for submission, regulatory bindings and require	eme	nts, '	Γool	and
	ronic dossier submission process and validating the submis				
	(ESG). None CTD electronic submissions (NeeS), Asian CTD				
_	zing, process and validation of submission. Submission in S	uga	m sy	stem	of
CDSCO.		1			
UNIT - III					
	, Definition, Summary, Types of audits, GMP compliance aud		Audi	t pol	icy,
	l Audits, Second Party Audits, External third-party audits, Audit				
	on and conducting audit, Auditing strategies, audit analysis, audi				
	liting/inspection of manufacturing facilities by regulatory agenci	ies.	Гimе	lines	for
	HTF study group 4 guidance document. ISO 13485				
UNIT - IV					
• • • •	roval inspections, Inspection of pharmaceutical manufacturers,	•			
_	annels, Quality systems requirements for national good manuf		_	_	
	ction report, model certificate of good manufacturing practi	ices,	Ko	ot ca	use
	and Preventive action (CAPA).				
UNIT - V	D' A 10 1 (710) 7		-	<u> </u>	
•	management: Prior Approval Supplement (PAS), Post Approval Sup	_			_
	Being Affected in 30 Days (CBE-30), Annual Report, Post man				
	approval Labeling Changes, Lifecycle Management, FDA	Ins	spect	10n	and
Enforcement, Establi	ishment Inspection Report (EIR), Warning Letters, Recalls,				

**Textbooks:** 

1. Compliance auditing for Pharmaceutical Manufacturers. Karen Ginsbury and Gil Bismuth, Interpharm/CRC, Boca Raton, London New York, Washington D.C.

Seizure and Injunctions. ISO Risk Management Standard



## JAWAHARLAL NEHRU TECHNOLOGICAL UNIVERSITY ANANTAPUR (Established by Govt. of A.P., ACT No.30 of 2008) ANANTHAPURAMU – 515 002 (A.P) INDIA

### M.PHARM. IN REGULATORY AFFAIRS

- 2. Pharmaceutical Manufacturing Handbook, Regulations and Quality by Shayne Cox Gad. Wiley- Interscience, A John Wiley and sons, Inc., Publications.
- 3. Handbook of microbiological Quality control. Rosamund M. Baird, Norman A. Hodges, Stephen
- 4. P. Denyar. CRC Press. 2000.
- 5. Laboratory auditing for quality and regulatory compliance. Donald C. Singer, Raluca-loana Stefan, Jacobus F. Van Staden. Taylor and Francis (2005).
- 6. Implementing Juran's Road Map for Quality Leadership: Benchmarks and Results, By Al Endres, Wiley, 2000
- 7. Understanding, Managing and Implementing Quality: Frameworks, Techniques and Cases, By Jiju Antony; David Preece, Routledge, 2002
- 8. Organizing for High Performance: Employee Involvement, TQM, Reengineering, and Knowledge Management in the Fortune 1000: The CEO Report By Edward E. Lawler; Susan Albers Mohrman; George Benson, Jossey-Bass, 2001
- 9. Corporate Culture and the Quality Organization By James W. Fairfield- Sonn, Quorum Books, 2001
- 10. The Quality Management Sourcebook: An International Guide to Materials and Resources By Christine Avery; Diane Zabel, Routledge, 1997
- 11. The Quality Toolbox, Second Edition, Nancy R. Tague, ASQ Publications
- 12. Juran's Quality Handbook, Sixth Edition, Joseph M. Juran and Joseph A. De Feo, ASQ Publications
- 13. Root Cause Analysis, The Core of Problem Solving and Corrective Action, Duke Okes, 2009, ASQ Publications
- 14. International Medical Device Regulators Forum (IMDRF) Medical Device Single Audit Program (MDSAP)



## JAWAHARLAL NEHRU TECHNOLOGICAL UNIVERSITY ANANTAPUR (Established by Govt. of A.P., ACT No.30 of 2008) ANANTHAPURAMU – 515 002 (A.P) INDIA

## M.PHARM. IN REGULATORY AFFAIRS

### **COURSE STRUCTURE & SYLLABI**

<b>Course Code</b>	REGULATORY PRACTICES AND	L	T	P	C
21S11105	DOCUMENTATION LAB	0	0	6	3
	Semester	I			

## **List of Experiments:**

- 1. Case studies (4 Nos.) of each of Good Pharmaceutical Practices.
- 2. Documentation for in process and finished products Quality control tests for Solid, liquid, Semisolid and Sterile preparations.
- 3. Preparation of SOPs, Analytical reports (Stability and validation)
- 4. Protocol preparation for documentation of various types of records (BMR, MFR, DR) Labeling comparison between brand & generics.
- 5. Preparation of regulatory dossier as per Indian CTD format and submission in SUGAM
- 6. Case studies on response with scientific rationale to USFDA Warning Letter
- 7. Preparation of submission checklist of IMPD for EU submission.
- 8. Comparison study of marketing authorization procedures in EU.



## JAWAHARLAL NEHRU TECHNOLOGICAL UNIVERSITY ANANTAPUR (Established by Govt. of A.P., ACT No.30 of 2008) ANANTHAPURAMU – 515 002 (A.P) INDIA

## M.PHARM. IN REGULATORY AFFAIRS

## **COURSE STRUCTURE & SYLLABI**

<b>Course Code</b>	DDIC DECHI ATODY AFFAIRS I AD	L	T	P	C
21S11106	DRUG REGULATORY AFFAIRS LAB	0	6	3	
Semester				[	

## **List of Experiments:**

- 1. Case studies on Change Management/ Change control. Deviations and Corrective & Preventive Actions (CAPA)
- 2. Import of drugs for research and developmental activities
- 3. GMP Audit Requirements as per CDSCO
- 4. Preparation of checklist for registration of IND as per ICH CTD format.
- 5. Preparation of checklist for registration of NDA as per ICH CTD format.
- 6. Preparation of checklist for registration of ANDA as per ICH CTD format.
- 7. Comparative study of DMF system in US, EU and Japan
- 8. Preparation of regulatory submission using eCTD software
- 9. Documentation of raw materials analysis as per official monographs
- 10. Preparation of audit checklist for various agencies
- 11. Preparation of submission to FDA using eCTD software
- 12. Preparation of submission to EMA using eCTD software
- 13. Preparation of submission to MHRA using eCTD software



## JAWAHARLAL NEHRU TECHNOLOGICAL UNIVERSITY ANANTAPUR (Established by Govt. of A.P., ACT No.30 of 2008) ANANTHAPURAMU – 515 002 (A.P) INDIA

## M.PHARM. IN REGULATORY AFFAIRS

## **COURSE STRUCTURE & SYLLABI**

<b>Course Code</b>	REGULATORY ASPECTS OF DRUGS &	L	T	P	C
21S11201	COSMETICS	4	0	0	4
	Semester	II			

## **Course Objectives:**

This course is designed to impart the fundamental knowledge on the drug development process, regulatory requirements for approval of new drugs, drug products and cosmetics in regulated and semi-regulated countries. It prepares the students to learn in detail on the regulatory requirements, documentation requirements, and registration procedures for marketing the drug products and cosmetics in regulated and semi-regulated countries.

## **Course Outcomes (CO):** Student will be able to

- Process of drug discovery and development and generic product development
- Regulatory approval process and registration procedures for API and drug products in US, EU
- Cosmetics regulations in regulated and semi-regulated countries
- A comparative study of India with other global regulated markets

### UNIT - I

USA & CANADA: Organization structure and functions of FDA. Federal register and Code of Federal Regulations (CFR), History and evolution of United States Federal, Food, Drug and Cosmetic Act (FFDCA), Hatch Waxman act and Orange book, Purple book, Drug Master Files (DMF) system in US, Regulatory Approval Process for Investigational New Drug (IND), New Drug Application (NDA), Abbreviated New Drug Application (ANDA), Supplemental New Drug Application (SNDA); Regulatory requirements for Orphan drugs and Combination Products, Changes to an approved NDA / ANDA. Regulatory considerations for manufacturing, packaging and labeling of pharmaceuticals in USA. Legislation and regulations for import, manufacture, distribution and sale of cosmetics in USA and Canada.

## UNIT - II

European Union & Australia: Organization and structure of EMA& EDQM, General guidelines, Active Substance Master Files(ASMF) system in EU, Content and approval process of IMPD, Marketing Authorization procedures in EU (Centralized procedure, Decentralized procedure, Mutual recognition procedure and National Procedure). Regulatory considerations for manufacturing, packaging and labeling of pharmaceuticals in EU, Eudral exdirectives for human medicines, Variations & extensions, Compliance of European Pharmacopoeia (CEP)/ Certificate of Suitability (CoS), Marketing Authorization (MA) transfers, Qualified Person (QP) in EU. Legislation and regulations for import, manufacture, distribution and sale of cosmetics in European Union& Australia.

## UNIT - III

Japan: Organization of the PMDA, Pharmaceutical Laws and regulations, types of registration applications, DMF system in Japan, drug regulatory approval process, Regulatory considerations for manufacturing, packaging and labeling of pharmaceuticals in Japan, Post marketing surveillance in Japan. Legislation and regulations for import, manufacture, distribution and sale of cosmetics in Japan

## UNIT - IV

Emerging Market: Introduction, Countries covered, Study of the world map, study of various committees across the globe (ASEAN, APEC, EAC, GCC, PANDRH, SADC)

WHO: WHO, GMP, Regulatory Requirements for registration of drugs and post approval requirements in WHO through prequalification programme, Certificate of Pharmaceutical Product(CoPP) - General and Country Specific (South Africa, Egypt, Algeria and Morocco, Nigeria, Kenya and Botswana)

UNIT - V



## JAWAHARLAL NEHRU TECHNOLOGICAL UNIVERSITY ANANTAPUR (Established by Govt. of A.P., ACT No.30 of 2008) ANANTHAPURAMU – 515 002 (A.P) INDIA

## M.PHARM. IN REGULATORY AFFAIRS

## **COURSE STRUCTURE & SYLLABI**

Brazil, ASEAN, CIS and GCC Countries: ASIAN Countries: Introduction to ACTD, Regulatory Requirements for registration of drugs and post approval requirements in China and South Korea & Association of Southeast Asian Nations (ASEAN) Region i.e. Vietnam, Malaysia, Philippines, Singapore and Thailand.

CIS (Commonwealth Independent States): Regulatory prerequisites related to Marketing authorization requirements for drugs and post approval requirements in CIS countries i.e.Russia, Kazakhstan and Ukraine GCC (Gulf Cooperation Council) for Arab states: Regulatory pre-requisites related to Marketing authorization requirements for drugs and post approval requirements in Saudi Arabia and UAE Legislation and regulations for import, manufacture, distribution and sale of cosmetics in Brazil, ASEAN, CIS and GCC Countries.

### **Reference Books:**

- 1. Generic Drug Product Development, Solid Oral Dosage forms, LeonShargel and IsaderKaufer, Marcel Dekker series, Vol.143
- 2. The Pharmaceutical Regulatory Process, Edited by Ira R. Berry MarcelDekker Series, Vol.144
- 3. The Pharmaceutical Regulatory Process, Second Edition Edited by Ira R.Berry and Robert P. Martin, Drugs and the Pharmaceutical Sciences, Vol. 185 Informa Health care Publishers.
- 4. New Drug Approval Process: Accelerating Global Registrations ByRichardAGuarino, MD, 5th edition, Drugs and the Pharmaceutical Sciences, Vol.190.
- 5. Guidebook for drug regulatory submissions / Sandy Weinberg. By JohnWiley& Sons. Inc.
- 6. Drugs: From Discovery to Approval, Second Edition By Rick Ng
- 7. New Drug Development: A Regulatory Overview, Eighth Edition ByMarkMathieu
- 8. Pharmaceutical Risk Management By Jeffrey E. Fetterman, Wayne L.Pines and Gary H. Slatko
- 9. Preparation and Maintenance of the IND Application in eCTD Format ByWilliam K. Sietsema
- 10. Country Specific Guidelines from official websites.
- 11. http://www.who.int/medicines/areas/quality\_safety/regulation\_legislation/ListMRAWebsites.pdf
- 12. Roadmap to an ASEAN economic community Edited by Denis Hew.ISEAS Publications, Singapore 2005, ISBN 981-230-347-2
- 13. ASEAN, Rodolfo C. Severino, ISEAS Publications, Singapore 2005, ISBN 978-981-230-750-7
- 14. Building a Future with Brics: The Next Decade for Offshoring, MarkKobayashi-Hillary, Springer
- 15. Outsourcing to India: The Offshore Advantage, Mark Kobayashi-Hillary, Springer Trade performance and Regional Integration of the CISCountries, Lev Freinkman,
- 16. The world Bank, Washington, DC, ISBN: 0-8212-5896-0
- 17. Global Pharmaceutical Policy: Ensuring Medicines for Tomorrow's WorldByFrederick M. Abbott, Graham Dukes, Maurice Nelson Graham Dukes
- 18. The Gulf Cooperation Council: A Rising Power and Lessons for ASEANby Linda Low and Lorraine Carlos Salazar (Nov 22, 2010)
- 19. Doing Business in the Asean Countries, BalbirBhasin, Business Expert Press ISBN:13:978-1-60649-108-9
- 20. Realizing the ASEAN Economic Community: A Comprehensive Assessment, Michael G Plummer (Editor), Chia Siow Yue (Editor), Instute of South east asian studies, Singapore



## M.PHARM. IN REGULATORY AFFAIRS

### **COURSE STRUCTURE & SYLLABI**

Course Code	REGULATORY ASPECTS OF HERBAL &	L	T	P	C
21S11202	BIOLOGICALS	4	0	0	4
	Semester		I	Ι	

## **Course Objectives:**

This course is designed to impart fundamental knowledge on Regulatory Requirements, Licensing and Registration, Regulation on Labelling of Biologics in India, USA and Europe It prepares the students to learn in detail on Regulatory Requirements for biologics, Vaccines and Blood Products

## **Course Outcomes (CO):** Student will be able to

- Know the regulatory Requirements for Biologics and Vaccines
- Understand the regulation for newly developed biologics and biosimilars
- Know the pre-clinical and clinical development considerations of biologics
- Understand the Regulatory Requirements of Blood and/or Its Components Including Blood Products and label requirements

### UNIT - I

India: Introduction, Applicable Regulations and Guidelines, Principles for Development of Similar Biologics, Data Requirements for Preclinical Studies, Data Requirements for Clinical Trial Application, Data Requirements for Market Authorization Application, Post-Market Data for Similar Biologics, Pharmacovigilance. GMP and GDP.

## UNIT - II

USA: Introduction to Biologics; biologics, biological and biosimilars, different biological products, difference between generic drug and biosimilars, laws, regulations and guidance on biologics/biosimilars, development and approval of biologics and biosimilars (IND, PMA, BLA, NDA, 510(k), pre-clinical and clinical development considerations, advertising, labelling and packing of biologics

## **UNIT - III**

European Union: Introduction to Biologics; directives, scientific guidelines and guidance related to biologics in EU, comparability/biosimilarity assessment, Plasma master file, TSE/ BSE evaluation, development and regulatory approval of biologics(Investigational medicinal products and biosimilars), pre-clinical and clinical development considerations; stability, safety, advertising, labelling and packing of biologics in EU

## UNIT - IV

Vaccine regulations in India, US and European Union: Clinical evaluation, Marketing authorisation, Registration or licensing, Quality assessment, Pharmacovigilance, Additional requirements Blood and Blood Products Regulations in India, US and European Union: Regulatory Requirements of Blood and/or Its Components Including Blood Products, Label Requirements, ISBT(International Society of Blood Transfusion) and IHN (International Haemovigilence Network)

## UNIT - V

Herbal Products: Quality, safety and legislation for herbal products in India, USA and European Union.

## **Textbooks:**

- 1. FDA Regulatory Affairs: A Guide for Prescription Drugs, Medical Devices, and Biologics, Douglas J. Pisano , David S. Mantus ; Informa ,2008
- 2. Biological Drug Products: Development and Strategies; WeiWang ,Manmohan Singh ; wiley ,2013
- 3. Development of Vaccines: From Discovery to Clinical Testing; ManmohanSingh ,Indresh K. Srivastava ;Wiley, 2011
- 4. www.who.int/biologicals/en
- $5.\ www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/$



## JAWAHARLAL NEHRU TECHNOLOGICAL UNIVERSITY ANANTAPUR (Established by Govt. of A.P., ACT No.30 of 2008) ANANTHAPURAMU – 515 002 (A.P) INDIA

## M.PHARM. IN REGULATORY AFFAIRS

- 6. www.ihn-org.com
- 7. www.isbtweb.org
- 8. Guidelines on Similar Biologics: Regulatory Requirements for Marketing Authorization in India
- 9. www.cdsco.nic.in
- 10. www.ema.europa.eu > scientific guidelines > Biologicals
- 11.www.fda.gov/biologics blood Vaccines/Guidance Compliance Regulatory Information (Biologics)



### M.PHARM. IN REGULATORY AFFAIRS

### **COURSE STRUCTURE & SYLLABI**

Course Code	REGULATORY ASPECTS OF MEDICAL	L	T	P	C
21S11203	DEVICES	4	0	0	4
	Semester		I	I	

## **Course Objectives:**

This course is designed to impart the fundamental knowledge on the medical devices and in vitro diagnostics, basis of classification and product life cycle of medical devices, regulatory requirements for approval of medical devices in regulated countries like US, EU and Asian countries along with WHO regulations. It prepares the students to learn in detail on the harmonization initiatives, quality and ethical considerations, regulatory and documentation requirements for marketing medical devices and IVDs in regulated countries.

## **Course Outcomes (CO):** Student will be able to

- Basics of medical devices and IVDs, process of development, ethical and quality considerations
- Harmonization initiatives for approval and marketing of medical devices and IVDs
- Regulatory approval process for medical devices and IVDs in India, US, Canada, EU, Japan and ASEAN
- Clinical evaluation and investigation of medical devices and IVDs

### UNIT - I

Medical Devices: Introduction, Definition, Risk based classification and Essential Principles of Medical Devices and IVDs. Differentiating medical devices IVDs and Combination Products from that of pharmaceuticals, History of Medical Device Regulation, Product Lifecycle of Medical Devices and Classification of Medical Devices.

IMDRF/GHTF: Introduction, Organizational Structure, Purpose and Functions, Regulatory Guidelines, Working Groups, Summary Technical Document (STED), Global Medical Device Nomenclature (GMDN).

### UNIT - II

Ethics: Clinical Investigation of Medical Devices, Clinical Investigation Plan for Medical Devices, Good Clinical Practice for Clinical Investigation of medical devices (ISO 14155:2011)

Quality: Quality System Regulations of Medical Devices: ISO13485, Quality Risk Management of Medical Devices: ISO14971, Validation and Verification of Medical device, Adverse Event Reporting of Medical device

## UNIT - III

USA: Introduction, Classification, Regulatory approval process for Medical Devices (510k) Premarket Notification, Pre-Market Approval (PMA), Investigational Device Exemption (IDE) and Invitro Diagnostics, Quality System Requirements 21 CFR Part 820, Labeling requirements 21 CFR Part 801, Post marketing surveillance of MD and Unique Device Identification (UDI). Basics of In vitro diagnostics, classification and approval process.

## **UNIT - IV**

European Union: Introduction, Classification, Regulatory approval process for Medical Devices(Medical Device Directive, Active Implantable Medical Device Directive) and In vitro Diagnostics (In Vitro Diagnostics Directive), CE certification process. Basics of In vitro diagnostics, classification and approval process.

## UNIT - V

ASEAN, China & Japan: Medical Devices and IVDs, Regulatory registration procedures, Quality System requirements and clinical evaluation and investigation. IMDRF study groups and guidance documents.

## **Textbooks:**



## JAWAHARLAL NEHRU TECHNOLOGICAL UNIVERSITY ANANTAPUR (Established by Govt. of A.P., ACT No.30 of 2008) ANANTHAPURAMU – 515 002 (A.P) INDIA

## M.PHARM. IN REGULATORY AFFAIRS

- 1. FDA regulatory affairs: a guide for prescription drugs, medical devices, and biologics by Douglas
- J. Pisano, David Mantus.
- 2. Medical Device Development: A Regulatory Overview by Jonathan S.Kahan
- 3. Medical Product Regulatory Affairs: Pharmaceuticals, Diagnostics, Medical Devices by John J. Tobin and Gary Walsh
- 4. Compliance Handbook for Pharmaceuticals, Medical Devices and Biologics by Carmen Medina
- 5. Country Specific Guidelines from official websites.



## M.PHARM. IN REGULATORY AFFAIRS

Course Code	REGULATORY ASPECTS OF FOOD &	L	T	P	С
21S11204	NUTRACEUTICALS	4	0	0	4
	Semester		I	I	
Course Objecti	ves:				
This course is	designed to impart the fundamental knowledge on Regula	tory	Requ	ireme	nts,
Registration and	Labeling Regulations of Nutraceuticals in India, USA and Euro	pe.			
It prepares the	students to learn in detail on Regulatory Aspects fornutra	ceuti	cals	and f	ood
supplements.					
Course Outcon	nes (CO): Student will be able to				
Know the re	gulatory Requirements for nutraceuticals				
<ul> <li>Understand</li> </ul>	the regulation for registration and labeling of nutraceuticals and	food	suppl	ement	s in
India, USA			• • •		
UNIT - I	•				
Nutraceuticals:	Introduction, History of Food and Nutraceutical Regula	tions.	Me	aning	of
	Dietary Supplements, Functional Foods, Medical Foods, Scope a				
Nutraceutical M			• •		
UNIT - II					
Global Aspects	: WHO guidelines on nutrition. NSF International: Its Ro	ole i	n the	Die	tary
Supplements and	d Nutraceuticals Industries, NSF Certification, NSF Standards for	or Foo	od An	d Die	tary
	ood Manufacturing Practices for Nutraceuticals.				·
UNIT - III					
India: Food Saf	ety and Standards Act, Food Safety and Standards Authority of	India	ı: Org	aniza	tion
and Functions,	Regulations for import, manufacture and sale of nutraceutical	l pro	ducts	in In	dia,
	Dietary Allowances (RDA) in India	-			
UNIT - IV					
USA: US FDA	Food Safety Modernization Act, Dietary Supplement Health	and I	Educa	tion 1	Act.
U.S. regulations	s for manufacture and sale of nutraceuticals and dietary sup	pleme	ents,	Label	ling
Requirements a	nd Label Claims for Dietary Supplements, Recommended I	Dietar	ry Al	lowar	ices
(RDA) in the U.	S				
UNIT - V					
	n: European Food Safety Authority (EFSA): Organization				EU
	egulations for manufacture and sale of nutraceuticals and dietary				
	ling. European Regulation on Novel Foods and Novel				nts.
Recommended I	Dietary Allowances (RDA) in Europe.				
Textbooks:					

- 1. Regulation of Functional Foods and Nutraceuticals: A Global Perspectiveby Clare M. Hasler (Wiley Online Library)
- 2. Nutraceutical and Functional Food Regulations in the United States and Around the World by Debasis Bagchi (Academic Press, Elsevier)
- 3. http://www.who.int/publications/guidelines/nutrition/en/
- 4.http://www.europarl.europa.eu/RegData/etudes/STUD/2015/536324/IPOL\_STU(2015)536324\_E N.pdf
- 5. Handbook of Nutraceuticals by Yashwant Pathak (CRC Press)
- 6. Food Regulation: Law, Science, Policy and Practice by Neal D. Fortin(Wiley)
- 7. Country Specific Guidelines from official websites.



## JAWAHARLAL NEHRU TECHNOLOGICAL UNIVERSITY ANANTAPUR (Established by Govt. of A.P., ACT No.30 of 2008) ANANTHAPURAMU – 515 002 (A.P) INDIA

### M.PHARM. IN REGULATORY AFFAIRS

## **COURSE STRUCTURE & SYLLABI**

<b>Course Code</b>	REGULATORY ASPECTS OF DRUGS &	L	T	P	C
21S11205	COSMETICS LAB	3	0	0	3
	Semester		]	Ί	•

## List of experiments

- 1. Preparation of documents required for Vaccine Product Approval
- 2. Comparison of clinical trial application requirements of US, EU and India of Biologics
- 3. Preparation of Checklist for Registration of Blood and Blood Products
- 4. Registration requirement comparison study in 5 emerging markets (WHO) and preparing check list for market authorization
- 5. Registration requirement comparison study in emerging markets (BRICS) and preparing check list for market authorization
- 6. Registration requirement comparison study in emerging markets (China and South Korea) and preparing check list for market authorization
- 7. Registration requirement comparison study in emerging markets (ASEAN) and preparing check list for market authorization
- 8. Registration requirement comparison study in emerging markets (GCC) and preparing check list for market authorization



## JAWAHARLAL NEHRU TECHNOLOGICAL UNIVERSITY ANANTAPUR (Established by Govt. of A.P., ACT No.30 of 2008) ANANTHAPURAMU – 515 002 (A.P) INDIA

## M.PHARM. IN REGULATORY AFFAIRS

## **COURSE STRUCTURE & SYLLABI**

<b>Course Code</b>	REGULATORY ASPECTS OF MEDICINAL DEVICES	L	T	P	C
21S11206	LAB	3	0	0	3
	Semester	II			

## **List of Experiments:**

- 1. Checklists for 510k and PMA for US market
- 2. Checklist for CE marking for various classes of devices for EU
- 3. STED Application for Class III Devices
- 4. Audit Checklist for Medical Device Facility
- 5. Clinical Investigation Plan for Medical Devices
- 6. Preparation and submission of medical devices for approval (3 products)
- 7. GMP of manufacturing of medical devices of diverse nature (3 products)
- 8. preparation and submission of nutraceuticals devices for approval (3 products)



## M.PHARM. IN REGULATORY AFFAIRS

## **COURSE STRUCTURE & SYLLABI**

	COURSE STRUCTURE & SYLLABI				
Course Code	RESEARCH METHODOLOGY AND	L	Т	P	С
21DRM101	INTELLECTUAL PROPERTY RIGHTS	4	0	0	4
	Semester			II	
<b>Course Objectives:</b>					
	nd the research problem				
	literature studies, plagiarism and ethics				
To get the ki	nowledge about technical writing				
To analyze to	he nature of intellectual property rights and new developments				
	patent rights				
<b>Course Outcomes (</b>	CO): Student will be able to				
Understand in	research problem formulation.				
Analyze rese	earch related information				
<ul> <li>Follow research</li> </ul>	arch ethics				
<ul> <li>Understand</li> </ul>	that today's world is controlled by Computer, Information	Tec	hnol	ogy,	but
tomorrow w	orld will be ruled by ideas, concept, and creativity.				
<ul> <li>Understanding</li> </ul>	ng that when IPR would take such important place in growth	of i	ndiv	idual	s &
nation, it is i	needless to emphasis the need of information about Intellectual	Prop	erty	Righ	nt to
be promoted	among students in general & engineering in particular.				
<ul> <li>Understand</li> </ul>	that IPR protection provides an incentive to inventors for furth	ier r	eseai	ch w	vork
and investm	ent in R & D, which leads to creation of new and better production	lucts	s, an	d in	turn
	, economic growth and social benefits.				
UNIT - I					
Research Problem					
Meaning of research	h problem, Sources of research problem, Criteria Character	istic	s of	a g	good
research problem, Ei	rrors in selecting a research problem, Scope and objectives of r	esea	rch j	probl	em.
Approaches of inv	vestigation of solutions for research problem, data coll	ectio	on,	analy	ysis,
interpretation, Neces	sary instrumentations				
UNIT – II					
Literature review					
Effective literature st	tudies approaches, analysis, Plagiarism, Research ethics.				
UNIT – III					
Report writing					
	riting, how to write report, Paper Developing a Research Propo	sal,	Forn	nat o	f
research proposal, a	presentation and assessment by a review committee				
UNIT – IV					
Nature of Intellectu	al Property				
Patents, Designs, T	rade and Copyright. Process of Patenting and Development	nt: 1	techi	olog	ical
	, patenting, development. International Scenario: Internationa	1 co	oper	ation	on
Intellectual Property	Procedure for grants of natants, Detenting under DCT				

Intellectual Property. Procedure for grants of patents, Patenting under PCT.

## UNIT – V

## **Patent Rights:**

Scope of Patent Rights. Licensing and transfer of technology. Patent information and databases. Geographical Indications. New Developments in IPR: Administration of Patent System. New developments in IPR; IPR of Biological Systems, Computer Software etc. Traditional knowledge Case Studies, IPR and IITs.

## **Textbooks:**



## JAWAHARLAL NEHRU TECHNOLOGICAL UNIVERSITY ANANTAPUR (Established by Govt. of A.P., ACT No.30 of 2008) ANANTHAPURAMU – 515 002 (A.P) INDIA

## M.PHARM. IN REGULATORY AFFAIRS

### **COURSE STRUCTURE & SYLLABI**

- 1. Stuart Melville and Wayne Goddard, "Research methodology: an introduction for science & engineering students'"
- 2. Wayne Goddard and Stuart Melville, "Research Methodology: An Introduction"

## **Reference Books:**

- 1. Ranjit Kumar, 2nd Edition, "Research Methodology: A Step by Step Guide for beginners"
- 2. Halbert, "Resisting Intellectual Property", Taylor & Francis Ltd ,2007.
- 3. Mayall, "Industrial Design", McGraw Hill, 1992.
- 4. Niebel, "Product Design", McGraw Hill, 1974.
- 5. Asimov, "Introduction to Design", Prentice Hall, 1962.
- 6. Robert P. Merges, Peter S. Menell, Mark A. Lemley, "Intellectual Property in New Technological Age", 2016.
- 7. T. Ramappa, "Intellectual Property Rights Under WTO", S. Chand, 2008



## JAWAHARLAL NEHRU TECHNOLOGICAL UNIVERSITY ANANTAPUR (Established by Govt. of A.P., ACT No.30 of 2008) ANANTHAPURAMU – 515 002 (A.P) INDIA

## M.PHARM. IN REGULATORY AFFAIRS

**COURSE STRUCTURE & SYLLABI** 

# AUDIT COURSE-I



## M.PHARM. IN REGULATORY AFFAIRS

Course Code	ENGLISH FOR RESEARCH PAPER WRITING	L	T	P	C
21DAC101a		2	0	0	0
	Semester		]	[	
Course Objectiv	es: This course will enable students:				
Understa	nd the essentials of writing skills and their level of readability				
<ul> <li>Learn ab</li> </ul>	out what to write in each section				
<ul> <li>Ensure q</li> </ul>	ualitative presentation with linguistic accuracy				
Course Outcome	es (CO): Student will be able to				
<ul> <li>Understa</li> </ul>	nd the significance of writing skills and the level of readability				
<ul> <li>Analyze</li> </ul>	and write title, abstract, different sections in research paper				
Develop	the skills needed while writing a research paper				
UNIT - I	• • • • • • • • • • • • • • • • • • • •	ectur	e Hrs	:10	
10verview of a	Research Paper- Planning and Preparation- Word Order- Useful P	hrase	es - E	Break	ing
up Long Sentenc	es-Structuring Paragraphs and Sentences-Being Concise and Remo	ving	Red	unda	ncy
-Avoiding Ambig	guity				
UNIT - II			e Hrs		
-	nents of a Research Paper- Abstracts- Building Hypothesis-Re			oblei	n -
Highlight Finding	gs- Hedging and Criticizing, Paraphrasing and Plagiarism, Cauteriz	ation	1		
UNIT - III			e Hrs		
	ew of the Literature - Methodology - Analysis of the Data-Find	ngs ·	- Dis	cussi	on-
Conclusions-Rec	ommendations.				
UNIT - IV	T	La	cture	I Ima i	`
	l for writing a Title, Abstract, and Introduction	Lec	Jure	nis.	1
UNIT - V	Too writing a Title, Abstract, and introduction	Ιω	cture	Hrc.(	<u> </u>
	luage to formulate Methodology, incorporate Results, put forth Arg	_			
Conclusions	uage to formulate victhodology, incorporate results, put forth Alg	zumc	mis a	na ai	avv
Suggested Read	ησ				
	R (2006) Writing for Science, Yale University Press (available on	Goo	gle F	Books	;)
	urriculum of Engineering & Technology PG Courses [Volume-I]		J-2 1		,
	006) How to Write and Publish a Scientific Paper, Cambridge Uni	versi	ty Pr	ess	
	N (1998), Handbook of Writing for the Mathematical Sciences, S				
Highman					
I .	Vallwork, English for Writing Research Papers, Springer New York	k Do	ordrec	cht	
Heidelbe	rg London, 2011				



## M.PHARM. IN REGULATORY AFFAIRS

### COURSE STRUCTURE & SYLLABI

<b>Course Code</b>	DICACRED MANAGEMENT		L	T	P	С
21DAC101b	DISASTER MANAGEMENT		2	0	0	0
		Semester	I			

## Course Objectives: This course will enable students:

- Learn to demonstrate critical understanding of key concepts in disaster risk reduction and humanitarian response.
- Critically evaluatedisasterriskreduction and humanitarian response policy and practice from Multiple perspectives.
- Developanunderstandingofstandardsofhumanitarianresponseandpracticalrelevanceinspecific types of disasters and conflict situations
- Criticallyunderstandthestrengthsandweaknessesofdisastermanagementapproaches, planning and programming in different countries, particularly their home country or the countries they work in

## UNIT - I

### **Introduction:**

Disaster:Definition,FactorsandSignificance;DifferenceBetweenHazardandDisaster;Naturaland Manmade Disasters: Difference, Nature, Types and Magnitude.

## **Disaster Prone Areas in India:**

Study of Seismic Zones; Areas Prone to Floods and Droughts, Landslides and Avalanches; Areas Prone to Cyclonic and Coastal Hazards with Special Reference to Tsunami; Post- Disaster Diseases and Epidemics

## UNIT - II

### **Repercussions of Disasters and Hazards:**

Economic Damage, Loss of Human and Animal Life, Destruction of Ecosystem. Natural Disasters: Earthquakes, Volcanisms, Cyclones, Tsunamis, Floods, Droughtsand Famines, Landslides and Avalanches, Man-made disaster: Nuclear Reactor Meltdown, Industrial Accidents, Oil Slicks and Spills, Outbreaks of Disease and Epidemics, War and Conflicts.

## **UNIT - III**

## **Disaster Preparedness and Management:**

Preparedness: Monitoring of Phenomena Triggering ADisasteror Hazard; Evaluation of Risk: Application of Remote Sensing, Data from Meteorological and Other Agencies, Media Reports: Governmental and Community Preparedness.

## **UNIT - IV**

## **Risk Assessment Disaster Risk:**

Concept and Elements, Disaster Risk Reduction, Global and National Disaster Risk Situation. TechniquesofRiskAssessment,GlobalCo-OperationinRiskAssessmentand Warning, People's Participation in Risk Assessment. Strategies for Survival.

## UNIT - V

## **Disaster Mitigation:**

Meaning, Conceptand Strategies of Disaster Mitigation, Emerging Trends In Mitigation. Structural Mitigation and Non-Structural Mitigation, Programs of Disaster Mitigation in India.

## **Suggested Reading**



## JAWAHARLAL NEHRU TECHNOLOGICAL UNIVERSITY ANANTAPUR (Established by Govt. of A.P., ACT No.30 of 2008) ANANTHAPURAMU – 515 002 (A.P) INDIA

## M.PHARM. IN REGULATORY AFFAIRS

- 1. R.Nishith, Singh AK, "Disaster Management in India: Perspectives, issues and strategies
- 2. "'New Royal book Company..Sahni,PardeepEt.Al.(Eds.),"DisasterMitigationExperiencesAndReflections",PrenticeHa ll OfIndia, New Delhi.
- 3. GoelS.L.,DisasterAdministrationAndManagementTextAndCaseStudies",Deep&Deep Publication Pvt. Ltd., New Delhi



## M.PHARM. IN REGULATORY AFFAIRS

<b>Course Code</b>	SANSKRI	FOR TECHNICAL KNOWLEDGE		L	T	P	C
21DAC101c				2	0	0	0
		Semest	er		]	[	
Course Objecti	ves: This course	will enable students:					
To get a	working knowle	edge in illustrious Sanskrit, the scientific l	ıngua	age in	the wo	rld	
<ul> <li>Learnin</li> </ul>	g of Sanskrit to i	mprove brain functioning					
<ul> <li>Learnin</li> </ul>	gofSanskrittodev	elopthelogicinmathematics,science&other	subje	ects er	hancin	g the	
memory	power						
• The eng	ineering scholars	s equipped with Sanskrit will be able to ex	plore	e the h	uge		
• Knowle	dge from ancient	literature					
<b>Course Outcon</b>	nes (CO): Studer	nt will be able to					
<ul> <li>Underst</li> </ul>	anding basic San	skrit language					
		re about science &technology can be unde	rstoo	od			
	logical language	will help to develop logic in students					
UNIT - I							
Alphabets in S	anskrit,						
UNIT - II							
	ure Tense, Simpl	e Sentences					
UNIT - III							
Order, Introduct	ion of roots						
UNIT - IV							
Technical info	mation about Sa	nskrit Literature					
UNIT - V							
Technical conc	epts of Engineeri	ng-Electrical, Mechanical, Architecture, M	lathe	matic	S		
Suggested Read	ling						
1."Abhyaspust	akam" –Dr.Visi	hwas, Sanskrit-Bharti Publication, Nev	v De	lhi			
2."Teach You	rself Sanskrit	"Prathama Deeksha-VempatiKutu	mbs	hastr	i, Rash	triyaSa	nskrit
,	lew Delhi Publi						
3."India's Gloa	rious Scientific	Tradition" Suresh Soni, Ocean books (	P) Lt	td.,Ne	w Dell	ni	



## JAWAHARLAL NEHRU TECHNOLOGICAL UNIVERSITY ANANTAPUR (Established by Govt. of A.P., ACT No.30 of 2008) ANANTHAPURAMU – 515 002 (A.P) INDIA

## M.PHARM. IN REGULATORY AFFAIRS

**COURSE STRUCTURE & SYLLABI** 

## AUDIT COURSE-II



## M.PHARM. IN REGULATORY AFFAIRS

## **COURSE STRUCTURE & SYLLABI**

ester	]	II	
esignandpol	icy makii	ng	
0 1	•	C	

## **Course Outcomes (CO):** Student will be able to

Students will be able to understand:

- Whatpedagogical practices are being used by teachers informal and informal class rooms in developing countries?
- What is the evidence on the effectiveness of these pedagogical practices, in what conditions, and with what population of learners?
- Howcanteachereducation(curriculumandpracticum)andtheschoolcurriculumand guidance materials best support effective pedagogy?

## UNIT - I

Introduction and Methodology: Aims and rationale, Policy back ground, Conceptual frame work and Theories oflearning, Curriculum, Teachereducation. Conceptual framework, Research questions. Overview of methodology and Searching.

## **UNIT - II**

Thematic overview: Pedagogical practices are being used by teachers in formal and classrooms in developing countries. Curriculum, Teacher education.

## **UNIT - III**

Evidence on theeffectivenessofpedagogical practices, Methodology for the indepth stage: quality assessment of included studies. How can teacher education (curriculumandpracticum) andthescho curriculum and guidance materials best support effective pedagogy? Theory of change. Strength and nature of th body of evidence for effective pedagogical practices. Pedagogic theory and pedagogical approaches. Teachers' attitudes and beliefs and Pedagogic strategies.

## UNIT - IV

**Professional development:** alignment with classroom practices and follow-up support, Peer support,

teacherandthecommunity.Curriculumandassessment,Barrierstolearning:limitedresourcesand large class sizes

## UNIT - V

Researchgapsandfuturedirections: Researchdesign, Contexts, Pedagogy, Teachereducation, Curriculum and assessment, Dissemination and research impact.

## **Suggested Reading**

- 1. AckersJ, HardmanF(2001)ClassroominteractioninKenyanprimaryschools, Compare, 31 (2): 245-261.
- AgrawalM(2004)Curricularreforminschools:Theimportanceofevaluation,Journalof



## JAWAHARLAL NEHRU TECHNOLOGICAL UNIVERSITY ANANTAPUR (Established by Govt. of A.P., ACT No.30 of 2008) ANANTHAPURAMU – 515 002 (A.P) INDIA

## M.PHARM. IN REGULATORY AFFAIRS

### **COURSE STRUCTURE & SYLLABI**

- 3. Curriculum Studies, 36 (3): 361-379.
- 4. AkyeampongK(2003) Teacher training in Ghana does it count? Multi-site teachereducation research project (MUSTER) country report 1. London: DFID.
- 5. Akyeampong K, LussierK, PryorJ, Westbrook J (2013)Improving teaching and learning of basic maths and reading in Africa: Does teacherpreparation count?International Journal Educational Development, 33 (3): 272–282.
- 6. Alexander RJ(2001) Culture and pedagogy: International comparisons in primary education. Oxford and Boston: Blackwell.
  - Chavan M (2003)ReadIndia: A mass scale, rapid, 'learning to read'campaign.

www.pratham.org/images/resource%20working%20paper%202.pdf.

31



## M.PHARM. IN REGULATORY AFFAIRS

<b>Course Code</b>	CED			L	T	P	C
21DAC201b	STR	ESSMANAGEMENT BY YOGA		2	0	0	0
		S	emester		I	I	
Course Objecti	ves: This course	e will enable students:					
To achie	eve overall heal	th of body and mind					
• To over	come stres						
<b>Course Outcom</b>	nes (CO): Stude	ent will be able to					
<ul> <li>Develop</li> </ul>	healthy mind i	n a healthy body thus improving soc	ial health a	also			
<ul> <li>Improve</li> </ul>	efficiency						
UNIT - I							
Definitions of I	Eight parts of yo	og.(Ashtanga)					
UNIT - II							
Yam and Niyar	n.						
UNIT - III							
Do`sand Don't	'sin life.						
		ncharyaand aparigrahaii) y,ishwarpranidhan					
UNIT - IV							
Asan and Prana	ıyam						
UNIT - V							
i)Variousyogpo	sesand theirben	nefitsformind &body					
ii)Regularizatio	onofbreathingted	chniques and its effects-Types ofpran	ayam				
Suggested Read							
		ning-Part-I": Janardan SwamiYogabh					
		e Internal Nature" by Swami Vi	vekananda	ı, Adv	aıta		
Ashrama (Public	cation Departme	ent), Kolkata					



## M.PHARM. IN REGULATORY AFFAIRS

Course Code 21DAC201c	PERSONALITY DEVELOPMENT THROUGHLIFE	L 2	T 0	P 0	C 0
210/102010	ENLIGHTENMENTSKILLS Semester		,	I	
	Semeste			<u>. I</u>	
Course Objecti	ves: This course will enable students:				
To learn	to achieve the highest goal happily				
	me a person with stable mind, pleasing personality and dete	rminatio	n		
	ken wisdom in students				
	nes (CO): Student will be able to				
	Shrimad-Bhagwad-Geetawillhelpthestudentindevelopinghis	personali	tyand a	chieve	
_	est goal in life				
_	son who has studied Geetawilllead the nation and mankind t	_	_	perity	
•	f Neetishatakam will help in developing versatile personality	of stude	ents		
UNIT - I					
	Holistic development of personality				
	20,21,22(wisdom)				
	31,32(pride &heroism)				
	28,63,65(virtue)				
UNIT - II					
	Holistic development of personality				
	53,59(dont's)				
	73,75,78(do's)				
UNIT - III					
* *	y to day work and duties.				
	nagwadGeeta:Chapter2-Verses41,47,48,				
Chapter3-V	Verses13,21,27,35,Chapter6-Verses5,13,17,23,35,				
	Verses45,46,48.				
UNIT - IV					
Statements of b	pasic knowledge.				
ShrimadBh	nagwadGeeta:Chapter2-Verses 56,62,68				
Chapter12	-Verses13,14,15,16,17,18				
Personality	of Rolemodel. Shrimad Bhagwad Geeta:	•			
UNIT - V					
Chapter2-V	Verses 17, Chapter 3-Verses 36, 37, 42,				
Chapter4-V	Verses18,38,39				
	- Verses37,38,63				
Suggested Read					
•	avadGita"bySwamiSwarupanandaAdvaitaAshram(Publicatio	nDepart	ment),		
Kolkata	1 0 (1 ATC :		1 %		
2.Bhartrihari's I Sansthanam,	hree Satakam (Niti-sringar-vairagya) by P.Gopinath, Rasi	ntriyaSar	iskrit		
Sansulanam,	New Delill.				



## JAWAHARLAL NEHRU TECHNOLOGICAL UNIVERSITY ANANTAPUR (Established by Govt. of A.P., ACT No.30 of 2008) ANANTHAPURAMU – 515 002 (A.P) INDIA

## M.PHARM. IN REGULATORY AFFAIRS

**COURSE STRUCTURE & SYLLABI** 

# OPEN ELECTIVE



### M.PHARM. IN REGULATORY AFFAIRS

### **COURSE STRUCTURE & SYLLABI**

<b>Course Code</b>	BIOLOGICAL SCREENING METHODS	L	T	P	C
21SOE301d	( Elective)	3	0	0	3
	Semester		I	Π	

## **Course Objectives:**

The students are going to study about various techniques for screening of drugs for various pharmacological activities and guide lines for handling animals and human and animal ethics for screening of drugs.

## **Course Outcomes (CO):** Student will be able to know

- How to handle animals
- About various techniques for screening of drugs for different pharmacological activities
- Guidelines and regulations for screening new drug molecules on animals.

### UNIT - I

## **Drug discovery process:**

Principles, techniques and strategies used in new drug discovery. High throughput screening, human genomics, robotics and economics of drug discovery, Regulations. Alternatives to animal screening procedures, cell-line, patch—clamp technique, In-vitro models, molecular biology techniques.

## UNIT – II

### **Bioassays:**

Basic principles of bioassays, official bioassays, experimental models and statistical designs employed in biological standardization.

## UNIT – III

## **Toxicity Evaluations**

Principles of toxicity evaluations, ED50, LD50 and TD values, International guidelines (ICH recommendations).

Preclinical studies: General principles and procedures involved in acute, sub-acute, chronic, teratogenicity, mutagenicity and carcinogenicity.

## UNIT - IV

## Screening of drugs

Screening of different classes of drugs using micro-organisms. Vitamin and antibiotic assays. Screening methods involved in toxins and pathogens.

## UNIT – V

## **Enzymatic screening methods**

 $\alpha$ -glucosidase,  $\alpha$ - amylase, DNA polymerase, nucleases, L-asparginase, lipases and peptidases.

## Reference Books:

- 1. Basic and clinical pharmacology by Bertram G. Katzung (International edition) lange medical book / Mc Graw Hill, USA 2001 8th edition
- 2. Pharmacology by Rang H.P, Dale MM and Ritter JM., Churchill Livingston, London, 4/e
- 3. Goodman and Gilman's The pharmacological basis of therapeutics (International edition) Mc Graw Hill, USA 2001 10th edition.
- 4. General and applid toxicology by B.Ballantyne, T.Marrs, P.Turner (Eds) The Mc Millan press Ltd, London.
- 5. Drug Discovery by Vogel's
- 6. Drug Discovery and evaluation Pharmacological assays by H.Gerhard. Vogel, 2nd edition, Springer verlag, Berlin, Heidelberg.
- 7. Tutorial Pharmacy (Vol I and II) by Cooper and Gunns.



### M.PHARM. IN REGULATORY AFFAIRS

## **COURSE STRUCTURE & SYLLABI**

Course Code	STABILITY OF DRUGS AND DOSAGE FORMS	L	T	P	C
21SOE301f	( Elective)	3	0	0	3
	Semester	III			

## **Course Objectives:**

These topics are designed impart a specialized knowledge to preserve the properties of drugs and dosage forms during manufacture storage and shelf life. The understanding of properties and evaluation of stability during storage, by solution and solid state against several factors of degradation.

## Course Outcomes (CO): Student will be able to

- Evaluation of stability of solutions, solids and formulations against adverse conditions.
- Suggest the measures to retain stability and storage conditions for retaining the efficacy of the products.

## UNIT – I

### **Drug decomposition mechanisms**

- 1. Hydrolysis and acyl transfers: Nature of reaction, structure and utility, stabilization of Pharmaceutical examples.
- 2. Oxidation: Nature of oxidation, kinetics of oxidation, oxidation pathways of pharmaceutical, Interest Inhibition of oxidation
- 3. Photolysis: Energetics of photolysis, kinetics photolysis, photolytic reactions of pharmaceutical interest, prevention of photolytic reactions.

## UNIT – II

## Solid state chemical decomposition

Kinetic of solids state decomposition, Pharmaceutical examples of solid-state decomposition, Pure drugs, drug excipient and drug-drug interaction in solid state, methods of stabilization.

Physical stability testing of dosage forms:

- 1. Solids tablets, capsules, powder and granules
- 2. Disperse systems
- 3. Microbial decomposition
- 4. Over-view, physical stability of novel drug carriers, liposomes, niosomes, nano-particles.

## UNIT – III

Identification and quantitative determination of preservatives, Antioxidants, colouring materials, emulsifiers and stabilizers in Pharmaceutical formulation.

Analysis of drugs from biological samples including, selection of biological sample, extraction of drugs by various methods as LLE, SPE and Membrane filtration. Factors affecting extraction of drugs.

## UNIT – IV

General method of analysis to determine the quality of raw materials used in cosmetic industry. Indian Standard Specifications (ISI) laid down for sampling and testing of various cosmetics in finished form by the Bureau of Indian Standards

## UNIT - V

Methods of analysis to determine the quality of cosmetics in the finished forms such as Hair care products, Skin care products, Baby care products, Dental products, Personal hygiene products, Colour cosmetics, Ethnic products, Colour makeup preparation, Lipsticks, Hair setting lotions and Eye shadows. Toxicity testing in cosmetics and Safety and Legislation of Cosmetic products.

Stability studies: Concept of stability studies.

- a) cGMP& ICH guidelines for Accelerated stability Testing.
- b) Interaction of containers & closure Compatibility Testing.



## JAWAHARLAL NEHRU TECHNOLOGICAL UNIVERSITY ANANTAPUR (Established by Govt. of A.P., ACT No.30 of 2008) ANANTHAPURAMU – 515 002 (A.P) INDIA

## M.PHARM. IN REGULATORY AFFAIRS

### **COURSE STRUCTURE & SYLLABI**

## **Reference Books:**

- 1. Comprehensive Pharmacy Review 5th Edition by Leon Shargel, Alan H. Mutnick, Paul F. Souney, Larry N. Sawnson 2004.
- 2. A.H. Beckett and J. B. Stenlake Practical Pharmaceutical Chemistry, Part I and Part II, 4<sup>th</sup> Edition.
- 3. G. H. Jeffery, J. Basset, J. Mendham, R. C. Denny (Rev. by) Vogels Text Book of Quantitative Chemical Analysis, 5th Edition 1989, ELBS.
- 4. The Controller of Publications; New Delhi, Govt. of India, Indian Pharmacopoeia, Vol. I and Vol. II 2010.
- 5. J. B. Wilkinson and R. J. Moore, Herry's Cosmeticology; Longman Scientific and Technical Publishers, Singapore.
- 6. P.D. Sethi; Quantitative Analysis of Drugs in Pharmaceutical Formulations, 3rd Edition 1997,
- 7. Classification of cosmetics raw materials and adjuncts IS 3958 of Indian Standards Institution (BIS).
- 8. Cosmetic and toilet goods methods of sampling IS 3958 of Indian Standards Institution (BIS).
- 9. Methods of sampling and test for various cosmetics as laid down by Bureau of Indian Standards.
- 10. Drug stability: Principles and practices by Jens T. Carstensen
- 11. Stability Testing of Drug Products by W. Grimm. 12. Stability of Drugs and Dosage Forms by Yoshioka and Stella.



## JAWAHARLAL NEHRU TECHNOLOGICAL UNIVERSITY ANANTAPUR (Established by Govt. of A.P., ACT No.30 of 2008) ANANTHAPURAMU – 515 002 (A.P) INDIA

## M.PHARM. IN REGULATORY AFFAIRS

## **COURSE STRUCTURE & SYLLABI**

Course Code	PHARMACOEPIDEMIOLOGY&	L	T	P	C
21SOE301e	PHARMACOECONOMICS (Elective-I)	3	0	0	3
	Semester	III			

## **Course Objectives:**

This course enables students to understand various pharmacoepidemiological methods and their clinical applications. Also, it aims to impart knowledge on basic concepts, assumptions, terminology, and methods associated with Pharmacoeconomics and health related outcomes, and when should be appropriate Pharmacoeconomic model should be applied for a health care regimen.

## Course Outcomes (CO): Student will be able to

- Understand the various epidemiological methods and their applications
- Understand the fundamental principles of Pharmacoeconomics.
- Identify and determine relevant cost and consequences associated with pharmacy products and services.
- Perform the key Pharmacoeconomics analysis methods
- Understand the Pharmacoeconomic decision analysis methods and its applications.
- Describe current Pharmacoeconomic methods and issues.
- Understand the applications of Pharmacoeconomics to various pharmacy settings.

### UNIT – I

## Introduction to Pharmacoepidemiology

Definition, Scope, Need, Aims & Applications; Outcome measurement: Outcome measures, Drug use measures: Monetary units, Number of prescriptions, units of drug dispensed, defined daily doses, prescribed daily doses, Diagnosis and Therapy surveys, Prevalence, Incidence rate, Monetary units, number of prescriptions, unit of drugs dispensed, defined daily doses and prescribed daily doses, medications adherence measurements.

## Concept of risk:

Measurement of risk, Attributable risk and relative risk, Time- risk relationship and odds ratio

## UNIT – II

## Pharmacoepidemiological Methods

Qualitative models: Drug Utilization Review; Quantitative models: case reports, case series, Cross sectional studies, Cohort and case control studies, Calculation of Odds' ratio, Meta-analysis models, Drug effects study in populations: Spontaneous reporting, Prescription event monitoring, Post marketing surveillance, Record linkage systems, Applications of Pharmacoepidemiology

### UNIT – III

## **Introduction to Pharmacoeconomics**

Definition, history of Pharmacoeconomics, Need of Pharmacoeconomic studies in Indian healthcare system. Cost categorization and resources for cost estimation: Direct costs. Indirect costs. Intangible costs. Outcomes and Measurements of Pharmacoeconomics: Types of outcomes: Clinical outcome, Economic outcomes, Humanistic outcomes; Quality Adjusted Life Years, Disability Adjusted Life Years Incremental Cost-Effective Ratio, Average Cost-Effective Ratio. Person Time, Willingness to Pay, Time Trade Off and Discounting.

## UNIT – IV

## Pharmacoeconomic evaluations

Definition, Steps involved, Applications, Advantages and disadvantages of the following Pharmacoeconomic models: Cost Minimization Analysis (CMA), Cost Benefit Analysis (CBA), Cost Effective Analysis (CEA), Cost Utility Analysis (CUA), Cost of Illness (COI), Cost Consequences



## JAWAHARLAL NEHRU TECHNOLOGICAL UNIVERSITY ANANTAPUR (Established by Govt. of A.P., ACT No.30 of 2008) ANANTHAPURAMU – 515 002 (A.P) INDIA

### M.PHARM. IN REGULATORY AFFAIRS

### **COURSE STRUCTURE & SYLLABI**

Analysis (COA).					
UNIT – V					

## Health related quality of life (HRQOL)

Definition, Need for measurement of HRQOL, Common HRQOL measures. Definition, Steps involved, Applications of the following: Decision Analysis and Decision tree, Sensitivity analysis, Markov Modeling, Software used in Pharmacoeconomic analysis, Applications of Pharmacoeconomics

## **Reference Books:**

- 1. Rascati K L. Essentials of Pharmacoeconomics, Woulters Kluwe rLippincott Williams & Wilkins, Philadelphia.
- 2. Thomas E Getzen. Health economics. Fundamentals and Flow of Funds. John Wiley & Sons, USA.
- 3. Andrew Briggs, Karl Claxton, Mark Sculpher. Decision Modeling for Health Economic Evaluation, Oxford University Press, London.
- 4. K G Revikumar, Pharmacoepidemiology and Pharmacoeconomics Concepts and Practices.
- 5. Michael Drummond, Mark Sculpher, George Torrence, Bernie O'Brien and Greg Stoddart. Methods for the Economic Evaluation of Health Care Programs Oxford University Press, London.
- 6. George E Mackinnon III. Understanding health outcomes and Pharmacoeconomics.
- 7. Graker, Dennis. Pharmacoeconomics and outcomes.
- 8. Walley, Pharmacoeconomics.
- 9. Pharmacoeconomic ed. by Nowakowska University of Medical Sciences, Poznan.
- 10. Relevant review articles from recent medical and pharmaceutical literature
- 11. Guru Prasad Mohanta and P K Manna, Textbook of Pharmacovigilance Concepts and Practice